Solid tumours pose a formidable challenge in the world of medicine, often resisting treatment due to the protective shield created by the tumour microenvironment. However, a groundbreaking collaboration between scientists in Brazil and India has yielded promising results, offering hope for a new approach to tackling these tumours.
The research, detailed in the Journal of Controlled Release, focuses on inhibiting the inflammatory tumour microenvironment (TME) to develop an alternative treatment for solid tumours. Professor Lúcia Helena Faccioli, from the University of São Paulo’s Ribeirão Preto School of Pharmaceutical Sciences in Brazil, explains, “Cells and molecules in the TME can fuel tumour growth, evading the body's natural defences.”The São Paulo Research Foundation (FAPESP) is committed to supporting scientific research across various fields in the State of São Paulo, Brazil. Through scholarships, fellowships, and grants, FAPESP empowers researchers and institutions to drive innovation and discovery. The collaborative effort, led by Faccioli and Avinash Bajaj from the Regional Centre for Biotechnology in Faridabad, India, resulted in the development of chimeric nano-micelles. These tiny particles, ranging from 1 to 100 nanometers, consist of phospholipids, docetaxel (DTX), a chemotherapy drug, and dexamethasone (DEX), an anti-inflammatory medication.
In laboratory tests on animals, these nano-micelles showed remarkable efficacy when administered intravenously. They not only reduced tumour size but also significantly extended survival rates. Faccioli highlights, “Untreated animals typically succumbed to tumours by days 28–30, whereas treated animals survived up to days 44–50.”
Avinash Bajaj underscores the impact of the treatment, stating, “The nano-micelles not only shrunk tumours but also altered the tumour microenvironment, enhancing the body's immune response against cancer cells.” Furthermore, they inhibited the secretion of inflammatory substances within the TME, thereby improving the anti-tumour action of certain defence cells.
Faccioli highlights that the compounds used in these nano-micelles have already received approval for human use, paving the way for further human studies. The collaboration involved institutions from both Brazil and India, reflecting the global effort to combat cancer.
With these promising results, the potential impact on human health is profound. Solid tumours, once a formidable obstacle in cancer treatment, may soon meet their match, offering renewed hope for patients worldwide.